Cargando…
Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12
For more than a decade, the cytokine interleukin-12 (IL-12) has been utilized, either alone or in combination with other drugs, as a treatment for cancer. The numerous anti-tumor properties of IL-12 still generate interest in the clinical use of this cytokine, even though it has demonstrated toxicit...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938584/ https://www.ncbi.nlm.nih.gov/pubmed/24587231 http://dx.doi.org/10.1371/journal.pone.0090116 |
_version_ | 1782305624331124736 |
---|---|
author | Barrios, Bibiana Baez, Natalia S. Reynolds, Della Iribarren, Pablo Cejas, Hugo Young, Howard A. Rodriguez-Galan, Maria Cecilia |
author_facet | Barrios, Bibiana Baez, Natalia S. Reynolds, Della Iribarren, Pablo Cejas, Hugo Young, Howard A. Rodriguez-Galan, Maria Cecilia |
author_sort | Barrios, Bibiana |
collection | PubMed |
description | For more than a decade, the cytokine interleukin-12 (IL-12) has been utilized, either alone or in combination with other drugs, as a treatment for cancer. The numerous anti-tumor properties of IL-12 still generate interest in the clinical use of this cytokine, even though it has demonstrated toxicity when administrated systemically. As an approach to overcome this toxicity, numerous laboratories have attempted to induce IL-12 expression at the site of the tumor. However for tumors that are difficult to remove surgically or for the treatment of disseminated metastases, systemic expression of this cytokine still remains as the most efficient method of administration. Nevertheless, finding alternative approaches for the use of IL-12 in the treatment of cancer and unraveling the basis of IL-12-side effects remain a challenge. In the present work we demonstrate that systemic expression of IL-12 through hydrodynamic injection of IL-12 cDNA is able to induce different types of liver lesions associated with a toxic pathology. However we report here that hepatic toxicity is diminished and survival of mice enhanced in the absence of tumor necrosis factor alpha (TNFα). This observation is in contrast to several murine models and clinical trials that postulate interferon gamma (IFNγ) as the main cytokine responsible for IL-12 toxicity. Moreover, our work demonstrates that when IL-12 cDNA is co-injected with IL-18 cDNA or when mice are pre-treated with a low dose of IL-12 cDNA prior to receiving a high dose of IL-12 cDNA, systemic levels of TNFα are almost completely abrogated, resulting in improved survival and less hepatic damage. Importantly, abrogation of TNFα signaling does not affect the strong anti-tumor activity of IL-12. Thus, neutralizing TNFα with antagonists already approved for human use offers a promising approach to abrogate IL-12 side effects during the use of this cytokine for the treatment of cancer. |
format | Online Article Text |
id | pubmed-3938584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-39385842014-03-04 Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 Barrios, Bibiana Baez, Natalia S. Reynolds, Della Iribarren, Pablo Cejas, Hugo Young, Howard A. Rodriguez-Galan, Maria Cecilia PLoS One Research Article For more than a decade, the cytokine interleukin-12 (IL-12) has been utilized, either alone or in combination with other drugs, as a treatment for cancer. The numerous anti-tumor properties of IL-12 still generate interest in the clinical use of this cytokine, even though it has demonstrated toxicity when administrated systemically. As an approach to overcome this toxicity, numerous laboratories have attempted to induce IL-12 expression at the site of the tumor. However for tumors that are difficult to remove surgically or for the treatment of disseminated metastases, systemic expression of this cytokine still remains as the most efficient method of administration. Nevertheless, finding alternative approaches for the use of IL-12 in the treatment of cancer and unraveling the basis of IL-12-side effects remain a challenge. In the present work we demonstrate that systemic expression of IL-12 through hydrodynamic injection of IL-12 cDNA is able to induce different types of liver lesions associated with a toxic pathology. However we report here that hepatic toxicity is diminished and survival of mice enhanced in the absence of tumor necrosis factor alpha (TNFα). This observation is in contrast to several murine models and clinical trials that postulate interferon gamma (IFNγ) as the main cytokine responsible for IL-12 toxicity. Moreover, our work demonstrates that when IL-12 cDNA is co-injected with IL-18 cDNA or when mice are pre-treated with a low dose of IL-12 cDNA prior to receiving a high dose of IL-12 cDNA, systemic levels of TNFα are almost completely abrogated, resulting in improved survival and less hepatic damage. Importantly, abrogation of TNFα signaling does not affect the strong anti-tumor activity of IL-12. Thus, neutralizing TNFα with antagonists already approved for human use offers a promising approach to abrogate IL-12 side effects during the use of this cytokine for the treatment of cancer. Public Library of Science 2014-02-28 /pmc/articles/PMC3938584/ /pubmed/24587231 http://dx.doi.org/10.1371/journal.pone.0090116 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Barrios, Bibiana Baez, Natalia S. Reynolds, Della Iribarren, Pablo Cejas, Hugo Young, Howard A. Rodriguez-Galan, Maria Cecilia Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title | Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title_full | Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title_fullStr | Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title_full_unstemmed | Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title_short | Abrogation of TNFα Production during Cancer Immunotherapy Is Crucial for Suppressing Side Effects Due to the Systemic Expression of IL-12 |
title_sort | abrogation of tnfα production during cancer immunotherapy is crucial for suppressing side effects due to the systemic expression of il-12 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938584/ https://www.ncbi.nlm.nih.gov/pubmed/24587231 http://dx.doi.org/10.1371/journal.pone.0090116 |
work_keys_str_mv | AT barriosbibiana abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT baeznatalias abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT reynoldsdella abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT iribarrenpablo abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT cejashugo abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT younghowarda abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 AT rodriguezgalanmariacecilia abrogationoftnfaproductionduringcancerimmunotherapyiscrucialforsuppressingsideeffectsduetothesystemicexpressionofil12 |